Navigation Links
Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
Date:4/14/2009

h multinational industrial manufacturing partners to rapidly secure substantially larger capacity in order to meet repeat and growing demand from existing and new customers worldwide.

Milestones

Neptune has achieved several value-creating milestones during fiscal year 2009:

NOVEL FOOD and PARNUTS approval granted for NKO(R)

NKO(R) has successfully passed rigorous regulatory review and scrutiny by all member states of the European Union (EU), which provided a positive opinion for NKO(R) as a NOVEL FOOD and PARNUTS allowing its commercialization at a clinically proven effective daily dose in all 27 European countries.

Formation of NeuroBioPharm for neurological applications

Neptune structured part of its pharmaceutical operations into its subsidiary NeuroBioPharm for cognitive function and neurological disease and is currently conducting a clinical study for a medical food product with a multinational partner.

Human clinical study demonstrates superior Neptune Krill Oil NKO(R)

pharmacokinetic profile

NKO(R) achieved a significantly higher bioavailability compared to successfully marketed nutraceutical and pharmaceutical omega-3 and NKO(R) like phospholipid formulations supporting the claim of the superiority of Neptune's omega-3 phospholipids.

Completion of $2.75 million private placement with 10% management

participation

The proceeds from this financing has been invested by Neptune in Acasti Pharma in order to reach several value-creating development and commercial milestones within Acasti Pharma's over-the-counter, prescription medical food and prescription drug programs.

Neptune and Marine Life Sciences enter alliance with Weider Global

Nutrition

Neptune and Marine Life Sciences have functional custom-built combinations of proprietary marine
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
...2008 - Book signing to follow his presentation, W...environment, elements of the global marketplace, a...Tech Conference., Wednesday panel presentations w...ry with the wireless & IT sectors, remote patient ...er when entering M&A transactions,China,s health c...
...Florida researcher may have found a defense agains...rd of Europe,s population in the Middle Ages and w...hreat today. , UCF Professor Henry Daniell and h...ch shows is highly effective against the plague. F...SDA funded research appear in the August edition o...
..., 2008 -- A new interactive web lesson teaches upp...nts how herbicides are developed. The lesson, deve..., has the seal of approval by the Journal of Natu...published in the 2008 issue. , Surprisingly, almo...discovered by random searching. Collections of che...
Other Biology Technology:Former Speaker of the House Newt Gingrich Featured Wednesday 2UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3
(Date:12/4/2009)By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
Breaking Biology News(10 mins):Scientists discover gene module underlying atherosclerosis development 2U-Iowa study helps advance heart-related research 2Lifelong memories linked to stable nerve connections 2 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 1 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 2 26quot 3BAprima Medical Software Inc 26quot 3B Unveiled by iMedica 3B Premier EHR PM Company Adopts New Name 51818 3Key Protein Might Shield Brain Cells 51813 1Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 1Hard To Treat Diseases 28HTDS PK 29 Tender Order To Indonesia 51808 2
...) The February edition of the Journal of Nutriti... between infant feeding and health outcomes relate....D., professor of clinical epidemiology at the Uni...vascular in the Department of Medicine at the Oreg...thors of the report, "A longer period of breastfee...
... a mathematical model of the mating game to help e...y, by researchers at UCL (University College Londo...f Economics and Political Science), shows that ext...bility to a female and enables the female to scree...he research, published this month in the Journal ...
...disease nephropathia epidemica (NE) has been linke...tter summers, milder winters and increased seedcro...d in BioMed Central,s open access International J...his rodent-borne disease to known effects of globa...f Microbiology & Immunology at Belgium,s Rega Inst...
Other Biology News:New infant feeding and obesity research adds insight to ongoing issue 2Why you can't hurry love 2Why you can't hurry love 3Global warming linked to European viral epidemic 2
Goat Anti-Human Serpin B5 / Maspin Polyclonal Antibody, Unconjugated from R&D Systems
...29 cm, 1. One system for gel staining and blot pr...ilver-stain gels for proteins and nucleic acid ana...ection and chromogenic detection. Programmable con... time.Proven design for consistent, high-quality p...
...SDA Research Registered OLAW Assured AAALAC Accred...LAS Certified Technicians Documentation GLP Proc...est Focus CRP is your one stop shopping point fo...fer free project consultation, free peptide sequen...
..., FHS-LVF, and the CVD-Diffuse We've combined our...ilters to create the world's first notch filter wi...bandpass. Each filter features an excellent transm...se filters -- with interference coatings applied t...
Biology Products: